4.5 Article

Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors

Journal

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 28, Issue 3, Pages 400-404

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2017.12.026

Keywords

Apoptosis signal-regulating kinase (ASK1); High throughput screening; Structure-based drug design; Kinase; Inhibitor

Funding

  1. NIH NIGMS [R01GM122109]

Ask authors/readers for more resources

The development of a new series of apoptosis signal-regulating kinase 1 (ASK1) inhibitors is described. Starting from purine, pyrimidine and quinazoline scaffolds identified by high throughput screening, we used tools of structure-based drug design to develop a series of potent kinase inhibitors, including 2-arylquinazoline derivatives 12 and 23, with submicromolar inhibitory activities against ASK1. Kinetic analysis demonstrated that the 2-arylquinazoline scaffold ASK1 inhibitors described herein are ATP competitive. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available